GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Market Cap

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Market Cap : $0.00 Mil (As of Apr. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anthera Pharmaceuticals's share price for the quarter that ended in Mar. 2018 was $0.32. Anthera Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2018 was 26.18 Mil. Therefore, Anthera Pharmaceuticals's market cap for the quarter that ended in Mar. 2018 was $8.38 Mil.

Anthera Pharmaceuticals's quarterly market cap increased from Sep. 2017 ($16.37 Mil) to Dec. 2017 ($22.86 Mil) but then declined from Dec. 2017 ($22.86 Mil) to Mar. 2018 ($8.38 Mil).

Anthera Pharmaceuticals's annual market cap declined from Dec. 2015 ($185.62 Mil) to Dec. 2016 ($29.82 Mil) and declined from Dec. 2016 ($29.82 Mil) to Dec. 2017 ($22.86 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anthera Pharmaceuticals's Enterprise Value for Today is $0.00 Mil.


Anthera Pharmaceuticals Market Cap Historical Data

The historical data trend for Anthera Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals Market Cap Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.61 36.35 185.62 29.82 22.86

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.26 17.17 16.37 22.86 8.38

Competitive Comparison of Anthera Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Anthera Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Market Cap falls into.



Anthera Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Anthera Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2017 is calculated as

Market Cap (A: Dec. 2017 )=Share Price (A: Dec. 2017 )*Shares Outstanding (EOP) (A: Dec. 2017 )
=$1.65*13.8545
=$22.86

Anthera Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2018 is calculated as

Market Cap (Q: Mar. 2018 )=Share Price (Q: Mar. 2018 )*Shares Outstanding (EOP) (Q: Mar. 2018 )
=$0.32*26.1793
=$8.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anthera Pharmaceuticals  (OTCPK:ANTH) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Anthera Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines